2222 Ponce de Leon Boulevard
Floor 3
Coral Gables, FL 33134
United States
786 629 1376
https://www.relmada.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 20
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director | 719.04k | N/A | 1960 |
Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer | 450.35k | N/A | 1964 |
Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer | 568.68k | N/A | 1965 |
Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | 1962 |
Ms. Gina DiGuglielmo | VP & Head of Clinical Operations | N/A | N/A | N/A |
Dr. Marco Pappagallo M.D. | Chief Clinical Officer | N/A | N/A | 1959 |
Mr. John Hixon | Head of Commercial | N/A | N/A | N/A |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 9. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 4; Compensation: 9.